Recombinant Human u-Plasminogen Activator/Urokinase Avi, CF

R&D Systems, part of Bio-Techne | Catalog # AVI1310

His-tag Avi-tag
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
AVI1310-020
Print Quote
Bulk Order
100% Guarantee

Key Product Details

  • R&D Systems HEK293-derived Recombinant Human u-Plasminogen Activator/Urokinase Avi (AVI1310)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession #

P00749.2

Conjugate

Biotin

Applications

Binding Activity, Enzyme Activity

View all u-Plasminogen Activator (uPA)/Urokinase Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human u-Plasminogen Activator (uPA)/Urokinase protein
Met1-Leu431 with C-terminal 6-His and Avi-tag

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Lys156 & Phe177

Predicted Molecular Mass

18 kDa (long A chain), 3 kDa (short A chain), 31 kDa (B chain)

SDS-PAGE

19-20 kDa & 32-38 kDa, under reducing conditions.

Activity

Measured by its ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).
The specific activity is >2000 pmol/min/μg, as measured under the described conditions.

Measured by its binding ability in a functional ELISA.
Biotinylated Recombinant Human u-Plasminogen Activator (uPA)/Urokinase His-tag Avi-tag (Catalog # AVI1310) binds to Human u-Plasminogen Activator (uPA) Antibody (Catalog # MAB1310) with an ED50 of 0.300-4.50 ng/mL.

Scientific Data Images for Recombinant Human u-Plasminogen Activator/Urokinase Avi, CF

Biotinylated Recombinant Human u‑Plasminogen Activator (uPA)/Urokinase His-tag Avi-tag Protein Enzyme Activity.

Recombinant Human u-Plasminogen Activator (uPA)/Urokinase His-tag Avi-tag (Catalog # AVI1310) is measured by its ability to cleave a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).

Biotinylated Recombinant Human u‑Plasminogen Activator (uPA)/Urokinase His-tag Avi-tag Protein Binding Activity.

In a functional ELISA, Biotinylated Recombinant Human u-Plasminogen Activator (uPA)/Urokinase His-tag Avi-tag Protein (Catalog # AVI1310) binds to Human u-Plasminogen Activator (uPA) Antibody (MAB1310) with an ED50 of 0.300-4.50 ng/mL

Formulation, Preparation and Storage

AVI1310
Formulation Supplied as a 0.2 μm filtered solution in HEPES, NaCl and CaCl2.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: u-Plasminogen Activator (uPA)/Urokinase

Urokinase Plasminogen Activator (uPA), also known as u-plasminogen activator or urokinase, is a highly-specific serine protease from the peptidase S1 family that cleaves plasminogen to form plasmin making it a key player in the plasminogen activator (PA) system (1, 2). In cancer, the PA system plays a commanding role in tumor growth, angiogenesis, tumor cell invasion, migration, and metastasis. Expression of uPA is minimal in normal cells but is increased several fold in tumor cells by extracellular stimuli elevated in cancer (3) and corresponds to poor outcomes in several types of cancer (2, 4-7). Therefore, uPA has been identified as an excellent target for therapeutic development through inhibition of protease activity or though inhibition of uPA-dependent signaling while in complex with uPA receptor (uPAR) (2, 7). The pro-enzyme of uPA is synthesized with a N-terminal signal peptide and processed into an active disulfide-linked two-chain molecule (2, 7-10). For human uPA, the B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). While the B chain is common for both forms, the long and short A chains are unique to expected 49 kDa and 34 kDa two-chain forms, respectively. The long A chain contains an EGF-like domain and the kringle domain. The long A domain is reportedly responsible for the binding of the uPA receptor (uPAR) (2,7). 

References

  1. Ellis, V. (2004) in Handbook of Proteolytic Enzymes. Barrett, A.J. et. al. eds., Academic Press, San Diego, pp.1677. 
  2. Mahmood, N. et. al. (2018) Front Oncol. 8:24.
  3. Nagamine, Y. et. al. (2005) Thromb. Haemost. 93:661.
  4. Duffy, M. and C. Duggan. (2004) Clin. Biochem. 37:541.
  5. Pappot, H. et. al. (2006) Lung Cancer 51:193.
  6. Taubert, H. et. al. (2010) Br. J. Cancer 102:731.
  7. Masucci, M.T. et. al. (2022) Cancers. 14:498.
  8. Riccio, A. et. al. (1985) Nucleic Acids Res. 13:2759.
  9. Nagai, M. et. al. (1985) Gene 36:183.
  10. Jacobs, P. et. al. (1985) DNA 4:139.

Long Name

Urokinase-type Plasminogen Activator

Alternate Names

PLAU, uPA, uPlasminogen Activator, Urokinase

Entrez Gene IDs

5328 (Human); 18792 (Mouse); 102135886 (Cynomolgus Monkey)

Gene Symbol

PLAU

UniProt

P00749.2

Additional u-Plasminogen Activator (uPA)/Urokinase Products

Product Documents for Recombinant Human u-Plasminogen Activator/Urokinase Avi, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human u-Plasminogen Activator/Urokinase Avi, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.